statements

Concord Drugs Ltd.

BSE: 538965

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

80.50+1.5 (+1.86%)

26 Aug, 3:30 PM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Concord Drugs Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	27.67	28.07	33.95	40.02	50.68	57.49	51.80	48.08	51.34	51.36	58.96	52.08	44.92	45.24	78.74	86.07
Cost of Operating Revenue	23.46	24.18	28.65	35.19	41.86	48.69	45.70	41.31	44.04	43.54	43.87	42.63	34.81	36.66	69.01	74.49
Gross Profit	4.21	3.89	5.30	4.84	8.83	8.80	6.10	6.77	7.30	7.81	15.09	9.45	10.12	8.58	9.72	11.58
Gross Margin	15.2	13.9	15.6	12.1	17.4	15.3	11.8	14.1	14.2	15.2	25.6	18.1	22.5	19.0	12.4	13.5
Total Operating Expenses	25.12	26.47	31.87	36.63	45.30	54.57	49.41	46.13	49.46	49.50	55.13	49.13	42.44	42.54	75.58	81.63
Operating Profit	2.55	1.60	2.09	3.40	5.38	2.92	2.39	1.95	1.88	1.85	3.83	2.95	2.49	2.70	3.15	4.44
Operating Margin	9.2	5.7	6.1	8.5	10.6	5.1	4.6	4.0	3.7	3.6	6.5	5.7	5.5	6.0	4.0	5.2
Financing Income/(Expense) - Net	-0.39	-0.52	-1.78	-2.72	-2.57	-2.42	-1.88	-1.59	-1.54	-1.42	-1.68	-1.71	-1.87	-2.03	-1.71	-1.62
Profit before Taxes	2.19	1.08	0.43	1.05	2.96	0.65	0.64	0.44	0.46	4.29	2.25	1.25	0.63	0.69	1.47	2.86
Income Taxes	0.59	0.04	0.09	0.35	1.21	0.49	0.31	0.03	0.13	1.01	0.65	0.26	0.16	0.36	0.42	0.81
Profit after Tax	1.59	1.04	0.34	0.70	1.75	0.16	0.32	0.41	0.33	3.28	1.59	0.99	0.47	0.34	1.06	2.05
PAT Margin	5.8	3.7	1.0	1.7	3.4	0.3	0.6	0.8	0.6	6.4	2.7	1.9	1.1	0.7	1.3	2.4
EPS - Basic - ex Extraordinary Items	2.20	1.44	0.47	0.96	2.41	0.22	0.41	0.52	0.38	3.75	1.82	1.06	0.47	0.34	0.95	1.67
EPS - Diluted - ex Extraordinary Items	2.20	1.44	0.47	0.96	2.41	0.22	0.41	0.52	0.38	3.75	1.82	1.06	0.47	0.34	0.95	1.67
EBIT	2.55	1.60	2.09	3.40	5.38	2.92	2.39	1.95	1.88	1.85	3.83	2.95	2.49	2.70	3.15	4.44
EBITDA	3.15	2.31	3.23	7.02	8.29	5.51	4.79	3.66	3.34	3.22	5.59	4.57	4.04	4.13	4.52	5.79
EBITDA Margin	11.4	8.2	9.5	17.5	16.4	9.6	9.2	7.6	6.5	6.3	9.5	8.8	9.0	9.1	5.7	6.7

Balance Sheet

Abridged

Understanding Balance Sheet

Concord Drugs Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	18.43	20.75	23.32	35.63	22.96	30.17	92.02	69.74	45.56	36.03	41.89	43.46	44.61	40.76	53.31
Long-Term Investments	-	-	-	-	0.79	0.79	0.79	0.79	0.79	0.64	0.64	1.53	1.48	1.44	1.42
Property Plant & Equipment - Net	8.16	19.32	20.84	18.32	14.39	12.85	12.72	11.35	10.74	13.19	13.88	13.20	12.67	13.57	13.37
Total Non-Current Assets	11.57	20.38	21.37	18.58	29.53	25.36	14.39	13.03	12.45	13.86	14.55	14.77	14.19	24.38	21.58
Total Assets	30.00	41.13	44.68	54.22	52.49	55.53	106.41	82.77	58.02	49.88	56.45	58.23	58.81	65.14	74.89
Total Current Liabilities	12.15	16.00	18.05	28.12	20.78	29.31	80.71	56.08	30.98	16.24	22.86	21.61	21.34	26.18	21.07
Long Term Debt	5.04	10.60	11.68	12.64	12.21	6.18	3.41	0.69	0.88	3.75	2.48	1.91	0.65	1.32	1.81
Total Non-Current Liabilities	5.04	10.90	12.06	12.77	16.65	6.54	5.76	2.99	3.10	6.51	5.23	4.91	3.65	4.85	5.31
Total Liabilities	17.19	26.90	30.11	40.90	37.43	35.85	86.47	59.07	34.08	22.75	28.08	26.53	24.99	31.03	26.37
Total Shareholders' Equity	12.81	14.24	14.57	13.32	15.07	19.68	19.94	23.70	23.94	27.14	28.36	31.70	33.82	34.11	48.51
Total Equity	12.81	14.24	14.57	13.32	15.07	19.68	19.94	23.70	23.94	27.14	28.36	31.70	33.82	34.11	48.51
Total Liabilities & Equity	30.00	41.13	44.68	54.22	52.49	55.53	106.41	82.77	58.02	49.88	56.45	58.23	58.81	65.14	74.89

Cash Flow

Abridged

Understanding Cash Flow Statement

Concord Drugs Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	2.39	2.09	3.35	4.07	4.70	0.48	2.74	2.03	1.79	5.18	3.33	2.49	1.95	1.90	2.39
Working Capital - Increase/(Decrease)	-5.60	-0.91	-1.07	-5.04	-4.23	-1.13	2.42	-2.33	-0.76	-4.81	-3.97	-2.46	-3.03	-0.21	-10.87
Net CF from Operating Activities	-3.21	1.18	2.28	-0.97	0.47	-0.66	5.17	-0.30	1.04	0.37	-0.64	0.03	-1.08	1.70	-8.48
Capital Expenditures - Net	2.44	9.65	2.14	1.10	-0.23	1.04	2.28	0.34	0.85	3.67	0.00	0.86	1.02	2.33	1.17
Net CF from Investing Activities	-2.44	-9.65	-2.14	-1.10	0.23	-1.04	-2.21	-0.34	-0.84	-3.67	0.01	-2.27	-1.01	-2.32	-1.13
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	2.97	-	0.88	-	-	1.89	0.68	-	3.17
Debt - LT & ST - Issuance/(Retirement) - Total	5.39	7.75	1.60	2.01	-0.85	-1.58	-3.02	-2.59	-0.26	3.40	3.46	-0.19	0.46	0.60	-3.59
Net Cash Flow from Financing Activities	6.14	7.62	-0.18	2.01	-0.85	-1.58	-3.08	0.76	-0.34	3.32	3.09	2.26	2.15	0.60	9.77
Free Cash Flow to Equity	-0.26	-0.71	1.75	-0.06	-0.14	-3.28	-0.13	-3.23	-0.07	0.10	2.82	-1.02	-1.64	-0.04	-13.24
Free Operating CF net dividend	-5.65	-10.70	-0.38	-2.07	-0.12	-1.70	2.89	-0.64	0.19	-3.30	-0.64	-0.83	-2.09	-0.64	-9.65
Free Operating CF	-5.65	-10.70	-0.38	-2.07	-0.12	-1.70	2.89	-0.64	0.19	-3.30	-0.64	-0.83	-2.09	-0.64	-9.65

Business Segment Analysis

Concord Drugs Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Concord Drugs Ltd.

Regional Segment Analysis

Concord Drugs Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Concord Drugs Ltd.

Historical Segment Analysis

Track how Concord Drugs Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Concord Drugs Ltd.

Frequently Asked Questions

What is the revenue of Concord Drugs Ltd.?

The latest trailing twelve month revenue of Concord Drugs Ltd. is ₹ 86.07 Cr, reflecting a 1-year growth of 82.51% and a 3-year CAGR of 21.04%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Concord Drugs Ltd.?

The latest trailing twelve month net profit (PAT) of Concord Drugs Ltd. is ₹ 2.05 Cr, with a 3-year earnings CAGR of 5.86%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Concord Drugs Ltd.?

The trailing twelve month EBITDA of Concord Drugs Ltd. is approximately ₹ 4.44 Cr (based on an operating margin of 5.16%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Concord Drugs Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Concord Drugs Ltd. is 1.67. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Concord Drugs Ltd.?

The debt-to-equity ratio of Concord Drugs Ltd. stands at 0.30. The interest coverage ratio is 2.74x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Concord Drugs Ltd.?

The estimated book value per share of Concord Drugs Ltd. is 49.42 (derived from a P/B ratio of 1.63 and market price of ₹ 80.50), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Concord Drugs Ltd.?

The trailing twelve month operating cash flow of Concord Drugs Ltd. is ₹ -8.48 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Concord Drugs Ltd. report consolidated or standalone financials?

Concord Drugs Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.